Login / Signup

Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.

Valliappan MuthuRatnakara Rao GogineniRitesh AgarwalKuruswamy Thurai PrasadInderpaul Singh SehgalSahajal DhooriaAshutosh N AggarwalShivaprakash Mandya RudramurthyHarkant SinghMandeep GargArunaloke Chakrabarti
Published in: Mycoses (2023)
Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.
Keyphrases
  • randomized controlled trial
  • study protocol
  • pulmonary hypertension
  • particulate matter
  • air pollution
  • heavy metals
  • phase iii
  • advanced non small cell lung cancer
  • gestational age
  • tyrosine kinase
  • replacement therapy